Yes Nebido is just Testosterone, albeit a 3-month injection.
But you will notice in that description, plus the recent phase III success, descriptions of the Efficacy endpoints, Safety too, and no mention at all of QoL/Distress. Plus it is not a Generic (in which case the goal of the trials would be bio-equivalency, which clearly they are not).
Beats me why Androxal could or should be held to a different standard.